P2.03-006 How Many Years of Life Have We Lost in Brazil Due to the Lack of Access to Anti-EGFR TKIs in the National Public Health System?

Abstract

Lung cancer is the fourth most common cancer in Brazil with 28,220 new cases in 2017. It is the main cause of cancer-related deaths with 23,393 deaths in 2013. In the 2000s, better understanding of molecular pathways led to the development of targeted treatments. The introduction of EGFR tyrosine kinase inhibitors (TKI) led to significant improvements in Response Rate and Progression-Free Survival for patients with activating mutations. Nevertheless, this treatment is not available in the Brazilian Public Health System based upon its costs and the absence of Overall Survival gain in randomized clinical trials.